University of Milano Bicocca
Associate Professor in Biochemistry and awarded of the habilitation as a Full professor in Biochemistry and Clinical Biochemistry,at the University of Milano Bicocca (Unimib), Department of Biotechnology and Bioscience.Principal investigator of the NanoBioLab of Unimib, he is devoted to biomedical and biophysical applications of nanotechnology. In particular, the research activity Prof.DavideProsperiinvolves the design, synthesis, functionalization and characterization of colloidal, polymeric and biomimetic nanoparticles for biomedical applications, with particular focus on the diagnosis and treatment of cancer and inflammatory diseases. He is an author of 100 scientific publications, including 86 research articles in peer-reviewed international scientific journals with impact factor and4 book chapters.Prof.DavideProsperi is one of the author of the patent “Nanoconstructs with pharmacological activity” (n° WO2014013473-A1), andhe is co-founder of the spin-off company inTHEnasrl, aiming to design and development of molecules, nanostructures and technologies for biomedical studies and diagnosis, prevention and therapy of human and animal diseases.
Prof. Prosperi’s main research interests regard application of nanotechnological and biotechnological tools in the field of human and animal diseases. In particular, he has developed a number of innovative approaches for biofunctionalization of colloidal and biomimetic nanoparticles, and has acquired excellent skills in different fields of molecular and cellular biology. A part from good experience in colloidal nanostructures, such as gold, silver and magnetic nanoparticles, he has been successfully working with recombinant proteins for targeting of different membrane proteins involved in fundamental cellular regulation mechanisms. Moreover, Prof. Prosperi is interested in study of mechanisms regulating tumor development and metastases as well as angiogenesis phenomena as a result of chemotherapeutic treatments in vivo. In this context, he has developed an innovative technology based on targeted delivery of nanovectors for preventing tumor development and differentiation, along with overcoming multidrug resistance in tumor cells. In collaboration with Prof. Granucci at the University of Milano-Bicocca, Prof. Prosperi has established a new research field focused on application of nanotechnology in immunology, in particular, study of inflammatory processes regulation by “Nuclear Factor of Activated T-cells” (NFAT) in innate and adaptive immune cells with the aim to evaluate their involvement in inflammatory disorders, such as transplant rejection, rheumatoid arthritis, Inflammatory Bowel Diseases, as well as neurodegenerative diseases as Alzheimer e Parkinson. Prof. Prosperi’s Lab contains 4 units: 1) Nanoparticle Synthesis unit, where development and synthesis of different colloidal, polymeric and biomimetic nanoparticles is carried out by well-known “wet chemistry” and genetic engineering techniques; 2) Targeting ligands unit, where recombinant proteins derived from antibodies and fusion proteins are developed for further conjugation to nanoparticles 3) Cell biology unit, working with a wide range of cell lines (cancerous and non-cancerous, BBB models) and, finally, 4) In vivo animal studies unit working with murine models of different tumors (breast, brain) and inflammatory diseases. Laboratory is fully equipped with modern instrumentation for nanoparticle synthesis and application.